Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | KRAS | P01116 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931118 | 0.86 | ELANE (0.43) | ELANEMAP2K4CDK1CCNB2CCNB1 | |
| SCHEMBL29439761 | 0.85 | PDGFRA (0.52) | ELANEMAP2K4CDK1CCNB2CCNB1 | |
| SCHEMBL1943689 | 0.85 | PDGFRA (0.52) | ELANEMAP2K4CDK1CCNB2CCNB1 | |
| SCHEMBL2732559 | 0.85 | CDK1 (0.43) | ELANEMAP2K4CDK1CCNB2CCNB1 | |
| SCHEMBL24148157 | 0.84 | ELANE (0.44) | ELANEMAP2K4CDK1CCNB2CCNB1 | |
| SCHEMBL18555671 | 0.84 | ELANE (0.52) | ELANEMAP2K4CDK1CCNB2CCNB1 | |
| SCHEMBL4300088 | 0.84 | ELANE (0.55) | ELANEMAP2K4CDK1CCNB2CCNB1 | |
| SCHEMBL29754066 | 0.84 | ELANE (0.52) | ELANEMAP2K4CDK1CCNB2CCNB1 | |
| SCHEMBL14773304 | 0.83 | ELANE (0.43) | ELANEMAP2K4CDK1CCNB2CCNB1 | |
| SCHEMBL20764732 | 0.83 | ELANE (0.43) | ELANEMAP2K4CDK1CCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585247-A | Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain | 赛特温治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4514789-A1 | <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4168411-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2021262684-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-8765786-B2 | 1-substituted indazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765786-B2 | 1-substituted indazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765786-B2 | 1-substituted indazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140121244-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121244-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121244-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121243-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121243-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121243-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| WO-2013154109-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2013-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121244-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | CHRNA3, CHRNB3, CHRNA7 | ELANE 2992/4885MAP2K4 2382/4885CDK1 2290/4885 |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | ELANE 1923/4885MAP2K4 3056/4885CDK1 1032/4885 |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | ELANE 1923/4885MAP2K4 3056/4885CDK1 1032/4885 |
| US-20140121243-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | CHRNA3, CHRNB3, CHRNA7 | ELANE 2992/4885MAP2K4 2382/4885CDK1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.